What is Ambrx Biopharma Inc. (AMAM)?

Ambrx Biopharma Inc. (AMAM) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of AMAM?

The current price of AMAM is $28.00. Prices are updated in real time on Stocks360.

What is AMAM's price-to-earnings (PE) ratio?

AMAM's trailing twelve-month PE ratio is -13.86, based on current price and earnings per share data available on Stocks360.

What is AMAM's market capitalization?

AMAM's market capitalization is $1,772,097,600.00, placing it in the small-cap tier.

Ambrx Biopharma Inc. (AMAM)

Stock analysis · NYSE · Healthcare · Biotechnology

$28.00

Market Cap

$1.77B

PE (TTM)

-13.86

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-2.36

Day Range

$27.98 – $28.00

52-wk Range

$6.55 – $28.15

Avg Volume

N/A

Volume

1.42M

Ambrx Biopharma Inc. (AMAM) is a publicly traded company in the Healthcare sector. Latest price: $28.00. Market cap $1.77B. Trailing PE -13.86. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Nov 16, 2023

EPS $-0.37 vs est. $-0.19

Missed by $0.18

Proprietary Signals

Signal snapshot temporarily unavailable.

About Ambrx Biopharma Inc.

Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies. Leading its pipeline is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is currently undergoing evaluation in several clinical investigations. These include pivotal Phase 2/3 trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer, alongside studies for other solid tumors. Additionally, Ambrx is progressing two earlier-stage drug candidates: ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for prostate cancer and other solid tumor indications; and ARX305, an anti-CD70 ADC, currently in investigational new drug (IND)-enabling studies for potential applications in renal cell carcinoma and other cancers. The company's portfolio also encompasses multiple immuno-oncology programs. Among these are ARX822, a fab-small molecule bispecific therapeutic in preclinical development for various cancers, and ARX102, an immuno-oncology IL-2 pathway agonist intended to stimulate the pa…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-13.86×
P/S (TTM)	239.41×
P/B	9.17×
P/FCF (TTM)	-25.41×
EV / EBITDA	-27.58×
EV / Sales	233.51×
Earnings Yield	-7.22%
Free Cash Flow Yield	-3.93%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.73B
Revenue (TTM)	$7.40M
Net Income (TTM)	-$127.86M
Free Cash Flow (TTM)	-$68.74M
Net Debt	-$43.63M
Working Capital	$73.92M
Gross Margin	100.00%
Operating Margin	-771.16%
Net Margin	-1053.72%
Return on Equity	-50.68%
Return on Invested Capital	-43.23%